+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 2Years - 16Years
All Genders
ID03647852

Treatment Study Comparing Methylprednisolone and IVIG for Children with Refractory Henoch-Schnlein Purpura with Abdominal Symptoms

Led by Children's Hospital of Fudan University · Updated on 2025-02-19

150

Participants Needed

3

Research Sites

35 weeks

Total Duration

AI-Summary

What This Trial Is About

IgA vasculitis is a condition that commonly affects children, particularly in Asian countries, and can cause serious abdominal problems like bleeding, pancreatitis, appendicitis, and intestinal intussusception. Delayed diagnosis may lead to severe complications or fatal outcomes. This trial aims to evaluate and compare treatment strategies for children with severe abdominal symptoms caused by IgA vasculitis, focusing on cost-effectiveness and clinical results. It is a multi-center, randomized, and controlled prospective study conducted in three childrens medical centers in Shanghai. Participants will be randomly assigned to one of two treatment groups one group receives methylprednisolone pulse therapy 15-30 mgkg per day for three days followed by oral prednisolone 2 mgkg per day, while the other group receives intravenous immunoglobulin IVIG at 2 gkg along with oral prednisolone at 2 mgkg per day. If abdominal pain persists after three days, the treatment may switch to the alternate therapy. Supportive treatments such as omeprazole and low molecular weight heparin calcium are also provided. Blood purification treatment will be considered if both primary therapies fail to relieve symptoms. During the study, participants will be monitored for abdominal pain relief at 3 and 7 days after treatment, medication side effects, infection, hypertension, ocular hypertension, steroid-related diabetes, and hospital stay length. Researchers will also evaluate food tolerance, fasting duration, and treatment costs. The total participation duration includes follow-up assessments up to 4 weeks after treatment to track these outcomes and assess the safety and effectiveness of the treatment strategies.

CONDITIONS

Brief Title

Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura

Research Team

L

Li Sun, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here